Onpattro (Patisiran)

Onpattro (patisiran) is covered for treatment of polyneuropathy due to hereditary transthyretin‑mediated amyloidosis in adults and is excluded for pediatric use, prior liver transplant recipients, and non‑FDA indications. Coverage requires genetic confirmation of hATTR, documented symptomatic polyneuropathy, prescription by or consultation with a neurologist/geneticist/amyloidosis specialist, dosing of 0.3 mg/kg IV every 3 weeks (max 30 mg), and authorization is granted for 12 months.

"Onpattro is indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults."

Sign up to see full coverage criteria, indications, and limitations.